Opioid Use Disorder (OUD) Market Report 2026

Opioid Use Disorder (OUD) Market Overview

• Opioid Use Disorder (OUD) market size has reached to $4.37 billion in 2025 • Expected to grow to $7.82 billion in 2030 at a compound annual growth rate (CAGR) of 12.5% • Growth Driver: Growing Number Of Opioid Addiction Cases • Market Trend: FDA Approval Of Brixadi Marks A Milestone In Opioid Use Disorder (OUD) Market Through Innovative Treatment Options • North America was the largest region in 2025.

What Is Covered Under Opioid Use Disorder (OUD) Market?

Opioid use disorder (OUD) is a chronic brain disease resulting from prolonged use of opioids, including both prescription painkillers and illegal opioids. Opioid use disorder can develop due to genetic, environmental, and behavioral factors. The main types of drugs for opioid use disorder (OUD) are buprenorphine, naltrexone, and methadone. Buprenorphine refers to a medication that belongs to the class of drugs known as opioids. Buprenorphine is used in the treatment of opioid use disorder (OUD) to reduce cravings and withdrawal symptoms associated with opioid dependence. They are administered through oral and parenteral routes for various age groups including 19 to 40, 41 to 60, 61 and over. It is distributed by hospital pharmacies, retail pharmacies and stores, and online pharmacies.

What Is The Opioid Use Disorder (OUD) Market Growth Forecast?

The opioid use disorder (oud) market size is expected to see rapid growth in the next few years. It will grow to $7.82 billion in 2030 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to rising government funding for addiction treatment programs, increasing acceptance of medication-assisted treatment, growth of online and telehealth-based addiction services, expanding insurance coverage for OUD therapies, increasing focus on preventive and harm reduction strategies. Major trends in the forecast period include rising adoption of medication-assisted treatment programs, increasing integration of behavioral therapy with pharmacological care, growing expansion of community-based opioid treatment centers, rising focus on long-acting injectable therapies for OUD, increasing emphasis on relapse prevention and long-term recovery care.

Global Opioid Use Disorder (OUD) Market Segmentation

1) By Drug Type: Buprenorphine, Naltrexone, Methadone 2) By Route Of Administration: Oral, Parenteral 3) By Age Group: 19 To 40, 41 To 60, 61 And Over 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Stores, Online Pharmacies Subsegments: 1) By Buprenorphine: Suboxone, Buprenorphine Tablets, Buprenorphine Film 2) By Naltrexone: Naltrexone Tablets, Vivitrol 3) By Methadone: Methadone Tablets, Methadone Oral Solution

What Is The Driver Of The Opioid Use Disorder (OUD) Market?

The growing number of opioid addiction cases is expected to propel the growth of the opioid use disorder (OUD) market going forward. Opioid addiction refers to a medical condition characterized by compulsive and chronic opioid use that has harmful effects on the body. Opioids can produce a sense of euphoria and pain relief, whose continued usage can lead to the development of tolerance, where higher doses are needed to achieve the same effect, which may lead to opioid use disorder. For instance, in 2023, according to the Centers for Disease Control and Prevention, a US-based public health agency, in 2023, number of drug overdose deaths involving any opioid is 79,358.Drug overdose deaths involving any opioid per 100,000 population is 23.7.Therefore, the growing number of opioid addiction cases drives the growth of the opioid use disorder (OUD) industry.

Key Players In The Global Opioid Use Disorder (OUD) Market

Major companies operating in the opioid use disorder (oud) market are Indivior Plc., Alkermes Inc., Braeburn Pharmaceuticals Inc., Titan Pharmaceuticals Inc., BioDelivery Sciences International Inc., Camurus AB, Orexo US Inc., Rhodes Pharmaceuticals L P, Mallinckrodt Pharmaceuticals, Hikma Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Viatris Inc., Mylan NV, Adapt Pharma Inc., Opiant Pharmaceuticals Inc., Dr Reddy’s Laboratories Ltd., Cipla Limited, Luye Pharma Group, Amneal Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Knight Therapeutics, BioCorRx Inc., Lannett Company Inc., Zydus Cadila, Apotex Inc., Intas Biopharmaceuticals, Glenmark Pharmaceuticals Ltd., InterveXion Therapeutics

Global Opioid Use Disorder (OUD) Market Trends and Insights

Major companies operating in the opioid use disorder (OUD) market are focusing on developing innovative solutions, such as next-generation extended-release buprenorphine formulations, to meet the rising demand for long-acting, adherence-supportive treatment options that reduce withdrawal symptoms and improve recovery outcomes. Extended-release buprenorphine formulations provide sustained medication delivery over weekly or monthly intervals, offering greater convenience and stability compared with daily oral or sublingual therapies that may increase relapse risk. For instance, in May 2023, the U.S. Food and Drug Administration, a US-based federal agency, approved Brixadi (buprenorphine) extended-release injection to treat moderate to severe opioid use disorder (OUD). Brixadi is available in two dosage forms a weekly injection for patients who began treatment with a single dose of a transmucosal buprenorphine product or who are currently taking the medication and a monthly version for those who are already receiving the medication.

What Are Latest Mergers And Acquisitions In The Opioid Use Disorder (OUD) Market?

In March 2023, Indivior PLC, a US-based pharmaceutical company, acquired Opiant Pharmaceuticals Inc. for $145 million. The acquisition is expected to help Indivior plc strengthen and extend its product offering for addiction treatment. Opiant Pharmaceuticals Inc. is a US-based pharmaceutical company that focuses on developing drugs for treating opioid overdose, acute cannabinoid overdose, and opioid use disorder.

Regional Outlook

North America was the largest region in the opioid use disorder (OUD) market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Opioid Use Disorder (OUD) Market?

The opioid use disorder (OUD) market consists of sales of bunavail, sublocade, suboxone, and zubsolv. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Opioid Use Disorder (OUD) Market Report 2026?

The opioid use disorder (oud) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the opioid use disorder (oud) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.